3-iodobenzylguanidine has been researched along with Myelodysplastic Syndromes in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Batra, V; DuBois, SG; Fetzko, S; Huibregtse, KE; Marachelian, A; Maris, JM; Matthay, KK; Neuhaus, J; Vo, KT; Weiss, B; Yanik, GA | 1 |
| Hawkins, RA; Huberty, J; Matthay, KK; Vora, A; Weiss, B | 1 |
1 trial(s) available for 3-iodobenzylguanidine and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidine.
Topics: 3-Iodobenzylguanidine; Adolescent; Adult; Age of Onset; Antineoplastic Agents; Child; Child, Preschool; Combined Modality Therapy; Female; Hematologic Neoplasms; Humans; Infant; Male; Myelodysplastic Syndromes; Neoplasms, Second Primary; Neuroblastoma; Radiopharmaceuticals; Retrospective Studies; Risk Assessment; Young Adult | 2016 |
1 other study(ies) available for 3-iodobenzylguanidine and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Secondary myelodysplastic syndrome and leukemia following 131I-metaiodobenzylguanidine therapy for relapsed neuroblastoma.
Topics: 3-Iodobenzylguanidine; Bone Marrow; Child; Chromosome Aberrations; Female; Follow-Up Studies; Humans; Infant; Leukemia, Radiation-Induced; Male; Myelodysplastic Syndromes; Neoplasms, Second Primary; Radionuclide Imaging; Radiopharmaceuticals; Recurrence; Time Factors | 2003 |